Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

124.66USD
4:01pm EDT
Change (% chg)

$-0.26 (-0.21%)
Prev Close
$124.92
Open
$124.74
Day's High
$125.43
Day's Low
$124.28
Volume
1,428,005
Avg. Vol
2,352,886
52-wk High
$129.00
52-wk Low
$107.70

Latest Key Developments (Source: Significant Developments)

Genmab A/S says Phase II study in NHL will not proceed
12:29pm EDT 

Genmab A/S : Phase II study of daratumumab in Non-Hodgkin’S Lymphoma will not proceed to stage 2 of trial . Genmab says Phase II study (CARINA, LYM2001) in NHL will not proceed . Genmab says other ongoing and planned studies with daratumumab in lymphomas and other cancers outside multiple myeloma continue as planned . Genmab says announcement has no impact on other ongoing or planned studies with daratumumab . Collaboration partner for daratumumab, Janssen Biotech, has decided not to initiate stage 2 of Phase II study (CARINA, LYM2001) of daratumumab . Study will not proceed to stage 2 based on results of a data review . Review showed 2 cohorts investigating use of daratumumab monotherapy in relapsed patients with FL, DLBCL didn't reach predefined ORR futility thresholds .In third cohort in study, patients with mantle cell lymphoma (MCL), ORR was not evaluable due to slow recruitment.  Full Article

Ligand announces licensing partner Janssen has filed an IND for an antibody discovered using the OmniAB Technology
Tuesday, 28 Mar 2017 09:00am EDT 

Ligand Pharmaceuticals Inc : Ligand announces licensing partner janssen has filed an IND for an antibody discovered using the OmniAB Technology .Ligand Pharmaceuticals Inc - IND filing results in $1 million milestone payment to Ligand.  Full Article

Actelion says drug discovery business to be called Idorsia
Wednesday, 15 Mar 2017 02:40am EDT 

Actelion Ltd :Says drug discovery and early clinical pipeline business will be separated into a newly-created entity called idorsia ltd -- agm invitation.  Full Article

Actelion says granted marketing authorization by European Commission for Ledaga
Tuesday, 7 Mar 2017 01:00am EST 

Actelion Ltd :Actelion is granted marketing authorization by the European Commission for Ledaga (chlormethine gel) for the treatment of MF-CTCL.  Full Article

Janssen provides Nuevolution with further technology access fee payment
Monday, 6 Mar 2017 02:30am EST 

Nuevolution AB (publ) : Nuevolution announces further technology access fee payment from its drug discovery collaboration with Janssen Biotech, Inc. (Janssen) . Janssen, one of pharmaceutical companies of Johnson & Johnson , has used its option to expand collaboration with Nuevolution .Janssen has provided Nuevolution with technology access fee payment of $0.6 million (5.45 million Swedish crowns).  Full Article

Johnson & Johnson says received a subpoena in Feb. from the U.S. attorney's office for the District of Massachusetts
Monday, 27 Feb 2017 04:59pm EST 

J&J : j&j - in february 2017, johnson & johnson received a subpoena from the united states attorney's office for the district of massachusetts . j&j-feb 2017 subpoena seeks records related to payments to any 501(c)(3) charitable organization that provides financial assistance to medicare patients . Says it plans to file a new shelf registration on feb 27, which will enable it to issue debt securities on a timely basis . J&J - anticipates operating cash flows, existing credit facilities, access to capital markets will provide sufficient resources to fund operating needs in 2017 . J&J-in connection with medical devices unit restructuring, to record pre-tax restructuring related charges of about $2.0 billion to $2.4 billion - sec filing . J&J - about one-half of cumulative pre-tax costs from restructuring to result in cash outlays, including about $500 million of employee severance . J&J - in jan 2017, janssen pharmaceuticals, inc. Received a civil investigative demand (cid) from the united states department of justice (doj) .J&J - subpoena to janssen pharmaceuticals relates to allegations concerning the "sales and marketing practices" of olysio.  Full Article

Ethicon announces agreement to acquire Torax Medical
Friday, 17 Feb 2017 10:00am EST 

Ethicon Inc : Ethicon announces agreement to acquire Torax Medical, Inc. .financial terms of transaction have not been disclosed.  Full Article

Swiss Takeover Commission OKs J&J offer for Actelion
Thursday, 16 Feb 2017 03:01am EST 

Actelion Ltd :Swiss Takeover Commission says J&J offer for Actelion meets legal requirements.  Full Article

Renova Therapeutics enters into agreement to receive Stresscopin investigational new drug file from Janssen
Monday, 6 Feb 2017 11:00am EST 

Renova Therapeutics : Enters into agreement to receive Stresscopin investigational new drug file from Janssen . Renova holds an exclusive license to Stresscopin Peptide from nonprofit research development foundation .Plans to advance development of Stresscopin program as RT-400,peptide infusion treatment for episodes of acute decompensated heart failure.  Full Article

BRIEF-J&J says upon termination of transaction agreement, under some circumstances, Actelion may be obligated to pay co a fee
Wednesday, 1 Feb 2017 04:05pm EST 

Corrects source to Johnson & Johnson from Actelion Ltd.Johnson & Johnson :J&J - upon termination of transaction agreement, under some circumstances, Actelion may be obligated to pay co a fee - sec filing.  Full Article

More From Around the Web

Photo

J&J, JPMorgan suspend YouTube ads over offensive videos

U.S. healthcare conglomerate Johnson & Johnson and JPMorgan Chase & Co became the latest big U.S. companies to suspend all digital advertising on Google's YouTube, over concerns that its ads may have appeared on channels that broadcast offensive videos. | Video